Introduction {#s1}
============

Somatic copy number alterations (CNAs) are nearly ubiquitous in cancer ([@bib43]; [@bib21]) and alter a greater portion of the cancer genome than any other type of somatic genetic alteration ([@bib21]). Different cancer types vary in their balance of copy number alterations to somatic point mutations, with prostate cancer having relatively high rates of CNA compared to point mutation. Given the prevalence of CNAs in cancer, significant effort has been directed towards identifying specific CNAs associated with cancer clinical characteristics and prognosis as well as the potential driver genes they contain ([@bib25]; [@bib40]; [@bib28]). There are well demonstrated associations between specific CNAs and CNA signatures to cancer state and characteristics ([@bib35]; [@bib41]; [@bib32]). CNV patterns or clusters have been associated with high Gleason prostate cancer (Gleason 8 + compared to Gleason 6--7 \[[@bib41]\]) and recurrent disease (compared to primary \[[@bib35]; [@bib10]; [@bib36]\]). Nonetheless, most CNAs are large, ([@bib43]; [@bib3]) and their associations with cancer outcome may not be well identified by gene-specific approaches. Increasing evidence indicates that large CNAs harbor multiple drivers ([@bib34]; [@bib26]), emphasizing the need to study their biological and clinical significance beyond individual gene-focused standpoints.

The CNA burden of a tumor is the degree to which a tumor\'s genome is altered as a percentage of genome length and represents a fundamental measure of genome copy number alteration level. As such, tumor CNA burden, rather than individual CNAs, may be associated with cancer outcomes. While tumor mutational burden (TMB) predicts response to immunotherapy across multiple cancer types ([@bib2]; [@bib20]), tumor CNA burden may be prognostic for outcomes such as recurrence and survival. Indeed, we and others have previously found CNA burden and genome-wide CNA patterns to be associated with biochemical recurrence and metastasis in primary prostate cancer, the most common cancer in men, across multiple cohorts ([@bib32]; [@bib22]; [@bib5]). This prognostic significance of tumor CNA burden extends to low and intermediate risk prostate cancer (Gleason scores of 7 and less) ([@bib22]) and has the potential to better stratify risk in patients who are considering conservative treatment approaches such as active surveillance to reduce overtreatment ([@bib13]; [@bib33]).

In addition to questions about the prognostic potential and overall landscape of CNA in conservatively treated prostate cancer, it is unknown whether CNA burden is prognostic for prostate cancer survival, rather than only recurrence and metastasis. Nor is it known whether the prognostic significance of tumor CNA burden extends to other cancer types. Here we set out to address these questions, as well as whether tumor CNA burden can be prognostic in a clinical practice setting, including (i) in cancers treated conservatively rather than through immediate surgery or radiation, (ii) in biopsy or resection samples, and (iii) using a clinical targeted sequencing that allows rapid and cost-effective measurement of tumor CNA burden.

To address these questions, we first examine the genomic CNA landscape of conservatively treated prostate cancer in more than a hundred diagnostic biopsy and resection specimens from a conservatively treated cohort; this cohort consisted of patients with localized prostate who were not treated with surgery or radiation within six months of diagnosis. We demonstrate that tumor CNA burden is associated with cancer-specific death, independent of standard clinical predictors. To explore the prognostic significance of tumor CNA burden more broadly in other cancer types, we find that tumor CNA burden is also associated with disease-free and overall survival in TCGA cohorts of primary breast, endometrial, renal clear cell, thyroid, and colorectal cancer in addition to prostate cancer, with the degree of association varying in some cancer types. We then establish the clinical feasibility of measuring tumor CNA burden using the FDA-cleared MSK-IMPACT clinical next generation sequencing (NGS) assay and confirm that tumor CNA burden is associated with overall and disease-specific survival in both primary and metastatic tumors across cancer types. In all, we demonstrate that tumor CNA burden is a prognostic factor associated with cancer recurrence and death in multiple cancer types, including in conservatively treated prostate cancer which would benefit from increased risk stratification.

Results {#s2}
=======

The genomic copy number landscape of conservatively treated prostate cancer {#s2-1}
---------------------------------------------------------------------------

To explore the genomic copy number landscape of conservatively treated prostate cancer, we set out to analyze copy number alteration (CNA) in cancer obtained non-surgically through biopsy and transurethral prostate resection (TURP) using a widely studied, conservatively treated primary prostate cancer cohort ([@bib17]). This retrospective Transatlantic Prostate Group 1 (TAPG1) cohort (n = 1675) consists of men below age 76 with clinically localized prostate cancer and prostate-specific antigen (PSA) below 100 ng/ml who did not receive surgery or radiation within 6 months of diagnosis ([@bib17]). This population-based cohort was drawn from six cancer registries in Great Britain, and the majority of the cohort was followed without treatment, while a subset received hormonal therapy. The original diagnostic samples, either biopsy or TURP, were obtained and centrally reviewed to obtain consistent pathological evaluation to the current standards. Drawing from this cohort, we carried out genome-wide CNA analysis by array-based comparative genomic hybridization (aCGH) of 107 biopsies or TURP samples from the TAPG1 cohort, as tissue availability is limited for much of the full cohort. The subset of cases used for CNA analysis, which make up our conservative treatment CNA cohort, have similar clinical characteristics to the full TAPG1 cohort, including median diagnosis age, baseline PSA, hormonal treatment, and clinical stage, with the exception of higher Gleason score distribution, likely due to selection for cases with sufficient DNA for analysis ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). As expected for a cohort not subject to PSA screening, the patients are older and have higher grade at diagnosis than is typical for contemporary US cohorts. Among the cohort, 47 patients developed metastasis and 43 died of prostate cancer. The median follow-up time for survivors was 10.3 years from diagnosis.

The copy number alteration landscape of the conservative treatment cohort revealed canonical copy number alterations of prostate cancer, including gain of chromosome 8q and losses on chromosomes 6 p, 8 p, 13q and 16 p, though with lower frequency than seen in prostate cancer cohorts analyzed by our group (MSKCC cohort) ([@bib32]) and TCGA ([@bib10]) ([Figure 1a](#fig1){ref-type="fig"}). The percentage of the cancer genome showing copy number changes, termed tumor CNA burden (TCB), is similar between the conservative treatment CNA cohort and other cohorts ([Figure 1b](#fig1){ref-type="fig"}), with a mean tumor CNA burden of 5.7% (median 1.5%, IQR 0.05--8.5%) compared to 5.2% (median 3.0%, IQR 0.04--6.9%) for the 2010 MSKCC primary prostate cancer cohort ([@bib32]) and 4.0% (median 0.7%, IQR 0.08--5.1%) for the 2014 MSKCC primary prostate cancer cohort ([@bib22]). The tumor CNA burden of the conservative treatment CNA cohort is, however, somewhat lower than the 8.7% average tumor CNA burden of the TCGA prostate cohort ([@bib10]) (mean 8.7%, median 6.2%, IQR 1.7--11.9%).

![Tumor copy number landscape of conservatively treated primary prostate cancer, compared to other primary prostate cancer cohorts.\
(**a**) Heat map of copy number alterations in conservative treatment CNA cohort, as well as TCGA, MSKCC, and IMPACT primary prostate cancer cohorts. (**b**) Frequency distribution of CNA burden, as log of percentage of genome copy number altered, for the conservative treatment prostate cancer cohort and three other primary prostate cancer cohorts.](elife-37294-fig1){#fig1}

Tumor CNA burden is prognostic for prostate cancer-specific death {#s2-2}
-----------------------------------------------------------------

Since tumor CNA burden is associated with prostate cancer recurrence and metastasis in prostatectomy cohorts ([@bib32]; [@bib22]), we sought to determine whether tumor CNA burden was prognostic for cancer-specific death in biopsies of conservatively treated prostate cancer. In our conservative treatment CNA cohort, we find that tumor CNA burden as a continuous variable is significantly associated with prostate cancer-specific death (per 5% tumor CNA burden, HR 1.49; 95% CI 1.30, 1.70; p\<0.0001; [Table 1](#table1){ref-type="table"}). Greater tumor CNA burden correlates with an increase in death from disease compared to a lower tumor CNA burden ([Figure 2a](#fig2){ref-type="fig"}). The risk of death due to prostate cancer within 5 years of diagnosis increases with tumor CNA burden over the majority of the tumor CNA burden distribution ([Figure 2b](#fig2){ref-type="fig"}). For example, the 5 year risk of death due to prostate cancer would be 13% for patients with a 2% tumor CNA burden and 28% for patients with a 10% tumor CNA burden ([Figure 2b](#fig2){ref-type="fig"}). Tumor CNA burden may therefore serve as a prognostic factor for cancer-specific death in patients who undergo increasingly common conservative treatment approaches.

![Tumor copy number alteration burden is associated with death from prostate cancer in conservatively treated patients.\
(**a**) Cumulative Incidence of death from disease (dashed lines) and death from other causes (solid lines) based in cases with high CNA burden (red lines, CNA Burden greater than or equal to the median CNA burden of this cohort, 1.48) or non-high CNA burden (black lines, CNA Burden \< median). (**b**) Risk for death from prostate cancer within 5 years of diagnosis. Univariate risk for 5 year prostate cancer-specific death, calculated by locally weighted Kaplan--Meier estimates (solid black line) with 95% confidence interval (dashed black lines) overlaid on the distribution of CNA burden (gray). (**c**) Association of tumor CNA burden with available cancer outcomes in the conservative treatment primary prostate cancer TAPG1 cohort, TCGA primary cancer cohorts, and the MSK-IMPACT clinical sequencing prostate and pan-cancer cohorts of primary and metastatic tumors. Forest plot of hazard ratio (per 5% CNA burden) with 95% confidence interval shown for cancer-specific mortality (dark blue), overall mortality (light blue), and cancer recurrence (green). Supplementary Tables and Figures.](elife-37294-fig2){#fig2}
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###### Tumor CNA burden is associated with prostate cancer-specific death in conservative treatment cohort independent of Gleason sum score and CAPRA score.

Cox Regression model assessing the association between CNA burden (per 5%) and cancer specific survival. N = 107\*

  -----------------------------------------------------------------------------------------------------------------------
  Model                                                                                    HR     95% CI       P-value
  ---------------------------------------------------------------------------------------- ------ ------------ ----------
  Univariate, tumor CNA burden                                                             1.49   1.30, 1.70   \<0.0001

  Multivariable -- adjusting for Gleason sum (≤6, 7, ≥8)                                   1.44   1.24, 1.67   \<0.0001

  Multivariable -- adjusting for UCSF-CAPRA score utilizing multiple imputation            1.44   1.24, 1.68   \<0.0001

  Multivariable -- adjusting for UCSF-CAPRA score without utilizing multiple imputation\   1.57   1.29, 1.92   \<0.0001
  \* N = 60 (excludes 47 patients with unknown stage)                                                          
  -----------------------------------------------------------------------------------------------------------------------

We next asked whether tumor CNA burden was associated with outcome after adjusting for established prognostic variables, including Gleason sum score and the UCSF Cancer of the Prostate Risk Assessment (CAPRA) score ([@bib16]; [@bib4]) which combines PSA, Gleason score, percentage positive biopsy cores, clinical stage, and age ([Figure 2c](#fig2){ref-type="fig"}). Tumor CNA burden is significantly associated with cancer-specific death even after adjusting for biopsy Gleason score (per 5% tumor CNA burden, HR 1.44; 95% CI 1.24, 1.67; p\<0.0001) or CAPRA score (per 5% tumor CNA burden, HR 1.44; 95% CI 1.24, 1.68; p\<0.0001) ([Table 1](#table1){ref-type="table"}, [Figure 2c](#fig2){ref-type="fig"}). The addition of tumor CNA burden into the model with the CAPRA score increased Harrell's concordance index from 0.756 to 0.805 for cancer-specific survival in our cohort of men with conservatively treated prostate cancer.

Tumor CNA burden is prognostic for cancer-free and overall survival in multiple cancer types {#s2-3}
--------------------------------------------------------------------------------------------

Large, clinically annotated cancer genomic efforts such as TCGA now provide an opportunity to examine whether CNA burden is prognostic for primary cancer outcomes across many cancer types. In the TCGA primary prostate cancer cohort ([@bib10]), tumor CNA burden is significantly associated with biochemical recurrence individually (p\<0.0001; per 5% tumor CNA burden, HR = 1.27; 95% CI, 1.13, 1.42) and after adjustment for Gleason score and mutation burden (p=0.015; per 5% tumor CNA burden, HR = 1.18; 95% CI, 1.03, 1.35), validating our findings from other prostate cancer cohorts ([Figure 2c](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, [Table 2](#table2){ref-type="table"}). There were insufficient deaths in this cohort to analyze survival. CNA burden was still significantly associated with biochemical recurrence after adjusting for tumor sample purity determined by ABSOLUTE (p\<0.003; per 5% CNA burden, HR = 1.22; 95% CI, 1.07, 1.40; [Table 2](#table2){ref-type="table"}). Since tumor CNA burden could potentially reflect simply the prognostic significance of aneuploidy as determined by cytometric DNA index in various cancers ([@bib39]; [@bib18]), we examined the tumor CNA burden in a multivariable model together with ploidy. Ploidy, generated by CLONET and previously published for this cohort, estimates the average DNA index of the tumor cells ([@bib11]; [@bib30]). Tumor CNA burden was associated with recurrence independent of tumor ploidy (p=0.002; per 5% tumor CNA burden, HR = 1.32; 95% CI 1.11, 1.56; [Table 2](#table2){ref-type="table"}). Moreover, for a multivariable model that includes tumor CNA burden, Gleason grade, and mutation burden, the Harrell's C-index is 0.691. In contrast, the C-index for a model including ploidy instead of tumor CNA burden is only 0.606, indicating that a model with clinical factors and ploidy does not perform as well as a model with the same clinical factors and tumor CNA burden.

10.7554/eLife.37294.011

###### Tumor CNA burden is associated with recurrence and overall survival independent of disease stage in multiple cancer types

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Cohort*                                                                                    *Model*                                                                              *Disease free Time*   *Overall Survival*                                                                                       
  ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ --------------------- -------------------- ------------ --------------------- ---------------------- ------------ ------------ ----------
  Prostate cancer TCGA                                                                        Tumor CNA burden, per 5% tumor CNA burden, univariate                                280                   1.27                 1.13, 1.42   \<0.0001              Insufficient events\                             
                                                                                                                                                                                                                                                                 \                                                
                                                                                                                                                                                                                                                                 \                                                

  Tumor CNA burden, per 5% tumor CNA burden, adjusted for Gleason grade and mutation burden   279                                                                                  1.18                  1.03, 1.35           0.015                                                                               

                                                                                              Tumor CNA burden, per 5% tumor CNA burden, adjusted for purity (ABSOLUTE)\*          243                   1.22                 1.07, 1.40   0.003                                                                  

                                                                                              Tumor CNA burden, per 5% tumor CNA burden, adjusted for ploidy                       243                   1.32                 1.11, 1.56   0.002                                                                  

  Breast cancer TCGA                                                                          Tumor CNA burden, per 5% tumor CNA burden, univariate                                709                   1.07                 1.01, 1.14   0.028                 794                    1.08         1.03, 1.13   0.0005

  Tumor CNA burden, per 5% tumor CNA burden, Multivariable, adjusted for disease stage        695                                                                                  1.07                  1.00, 1.14           0.049        777                   1.08                   1.03, 1.13   0.002        

  Endometrial Cancer TCGA                                                                     Tumor CNA burden, per 5% tumor CNA burden, univariate                                496                   1.10                 1.06, 1.14   \<0.0001              536                    1.13         1.08, 1.17   \<0.0001

  Tumor CNA burden, per 5% tumor CNA burden, multivariable, adjusted for disease stage        496                                                                                  1.08                  1.04, 1.13           \<0.0001     536                   1.10                   1.05, 1.15   \<0.0001     

  Renal clear cell cancer TCGA                                                                Tumor CNA burden, per 5% tumor CNA burden, univariate                                425                   1.05                 1.01, 1.09   0.028                 525                    1.02         0.98, 1.06   NS (0.4)

  Tumor CNA burden, per 5% tumor CNA burden, multivariable, adjusted for disease stage        423                                                                                  1.05                  1.00, 1.11           0.035        522                   1.01                   0.97, 1.06   NS (0.7)     

  Thyroid cancer TCGA                                                                         Tumor CNA burden, per 5% tumor CNA burden, univariate                                483                   1.17                 1.01, 1.35   0.033                 497                    1.30         1.04, 1.63   0.021

  Tumor CNA burden, per 5% tumor CNA burden, multivariable, adjusted for disease stage        481                                                                                  1.18                  1.00, 1.39           0.048        Insufficient events                                                    

  Colorectal cancer TCGA                                                                      Tumor CNA burden, per 5% tumor CNA burden, univariate                                512                   1.05                 1.00, 1.11   0.037                 587                    1.06         1.01, 1.12   0.012

  Tumor CNA burden, per 5% tumor CNA burden, multivariable, adjusted for disease stage        496                                                                                  1.03                  0.98, 1.09           NS (0.3)     567                   1.03                   0.97, 1.09   NS (0.3)     

                                                                                              Tumor CNA burden, per 5% tumor CNA burden, multivariable, adjusted for tumor stage   511                   1.06                 1.01, 1.12   0.028                 585                    1.07         1.02, 1.13   0.009
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Result differed with similar adjustment in IMPACT prostate cancer cohort utilizing FACETS, see [Supplementary file 3](#supp2){ref-type="supplementary-material"}.

The prognostic significance of tumor CNA burden in prostate cancer led us to ask whether tumor CNA burden is prognostic in other cancer types. Towards this end, we examined published TCGA cohorts for multiple cancer types with available disease-free survival and overall survival data, including breast ([@bib15]), endometrial ([@bib8]), renal clear cell ([@bib7]), thyroid ([@bib9]), and colorectal ([@bib6]) cancers. We found that tumor CNA burden is associated with recurrence (disease-free survival) in these cancer types ([Figure 2c](#fig2){ref-type="fig"}, [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, [Table 2](#table2){ref-type="table"}). This association between tumor CNA burden and lower disease-free survival was independent of disease stage in all cancer types except colorectal cancer, where the association was independent of tumor stage but not disease stage ([Table 2](#table2){ref-type="table"}). In addition to lower disease-free survival, higher tumor CNA burden was also significantly associated with lower overall survival in breast, endometrial, thyroid, and colorectal cancer ([Table 2](#table2){ref-type="table"}). This association with overall survival was independent of disease stage in breast and endometrial cancer and independent of tumor stage in colorectal cancer ([Table 2](#table2){ref-type="table"}). There were insufficient cases of thyroid cancer with stage data for this analysis. In summary, tumor CNA burden is prognostic for recurrence and/or overall survival in multiple cancer types beyond prostate cancer, including breast, endometrial, colorectal, renal clear cell, and thyroid cancer.

Tumor CNA burden determined by clinical targeted sequencing of primary and metastatic tumors is prognostic for survival {#s2-4}
-----------------------------------------------------------------------------------------------------------------------

We next wanted to determine whether CNA burden's prognostic associations could be observed using panel-based targeted sequencing assays that are increasingly entering clinical use, in contrast to CGH array-based determination of tumor CNA burden. The Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) assay is a clinical laboratory improvement amendments (CLIA)-certified sequencing-based assay ([@bib14]) of several hundred cancer genes and 1042 common single nucleotide polymorphisms (SNPs) that has been used to profile 504 prostate tumors ([@bib1]) and more than ten thousand tumors across other cancer types ([@bib44]). The IMPACT assay identifies both somatic point mutations and copy number alterations in the genes included in the panel. Overall copy number burden is calculated across the whole genome ([Figure 1a](#fig1){ref-type="fig"}) using segmentation derived from a combination of the profiled SNPs to provide low resolution copy number data and the genes sequenced in the panel ([@bib14]; [@bib1]; [@bib44]). To address the possibility that CNA burden from the IMPACT panel might differ from that derived from more comprehensive sequencing, we directly compared CNA burden calculations from 1005 tumors that were profiled using both IMPACT and whole exome sequencing. CNA burden determined by the two methods were highly correlated (p-value\<0.0001, rho = 0.88, n = 1005), indicating that CNA burden is not significantly affected by the reduced resolution in moving from whole exome to targeted panel sequencing ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}).

We find that tumor CNA burden assayed by targeted clinical sequencing is significantly associated with overall survival in primary prostate tumors (per 5% tumor CNA burden, HR = 1.17; 95% CI, 1.04, 1.3; p=0.007; [Table 3](#table3){ref-type="table"}, [Figure 2c](#fig2){ref-type="fig"}, [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}) in the IMPACT prostate cohort ([@bib1]). As clinical sequencing assays such as MSK-IMPACT are principally used in the metastatic patient population, the IMPACT cohorts also provide an opportunity to investigate the prognostic significance of tumor CNA burden in late stage disease. We find that tumor CNA burden of metastatic prostate tumors assayed by clinical sequencing is also significantly associated with survival (per 5% tumor CNA burden, HR = 1.07; 95% CI, 1.01, 1.14; p=0.020; [Table 3](#table3){ref-type="table"}, [Figure 2c](#fig2){ref-type="fig"}, [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}).

10.7554/eLife.37294.012

###### Tumor CNA burden determined by clinically approved sequencing panel is associated with overall survival in primary and metastatic tumors

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Model*                                                                        *Overall Survival*                                                      
  ------------------------------------------------------------------------------ -------------------- ------------- -------------- ------- ------------- -------------
  Prostate Cancer^\*,†^                                                                                                                                  

  Univariate, tumor CNA burden, per 5%                                           1.17                 1.04, 1.31    0.007          1.07    1.01, 1.14    0.020

  Multivariable\                                                                 1.11\                0.98, 1.26\   0.10\          1.08\   1.02, 1.15\   0.011\
  Tumor CNA burden, per 5%\                                                      1.22                 1.12, 1.33    \<0.0001       1.05    1.02, 1.08    0.001
  Mutation burden (per mutation)                                                                                                                         

  Multivariable\                                                                 1.17\                1.04, 1.31\   0.007\         1.06\   1.00, 1.13\   NS (0.069)\
  Tumor CNA burden, per 5%\                                                      4.12                 2.02, 8.41    \<0.0001       1.24    0.76, 2.02    NS (0.4)
  *TP53* CN loss or mutation                                                                                                                             

  Multivariable\                                                                 1.15\                1.02, 1.30\   0.026\         1.06\   0.99, 1.13\   NS (0.091)\
  Tumor CNA burden, per 5%\                                                      3.24                 0.70, 14.98   NS (0.13)      1.68    0.94, 2.99    NS (0.080)
  *RB1* CN loss or mutation                                                                                                                              

  Multivariable\                                                                 1.17\                1.04, 1.32\   0.008\         1.07\   1.01, 1.14\   0.023\
  Tumor CNA burden, per 5%\                                                      2.38                 1.03, 5.51    0.042          1.15    0.70, 1.89    NS (0.6)
  *PTEN* CN loss or mutation                                                                                                                             

  Pan- Cancer                                                                                                                                            

  Univariate, tumor CNA burden, per 5%^‡§^                                       1.04                 1.02, 1.05    \<0.0001       1.02    1.01, 1.03    0.005

  Univariate, mutation burden (per five units)^‡§^                               0.98                 0.97, 1.00    NS (0.072)     0.99    0.97, 1.01    NS (0.4)

  Meta-analysis, tumor CNA burden (per 5%)^\#^                                   1.04                 1.02, 1.05    \<0.0001\*\*   1.02    1.01, 1.04    0.005^††^

  Meta-analysis, tumor CNA burden (per 5%), excluding outlier cancer types^‡‡^   1.05                 1.03, 1.07    \<0.0001^§§^   1.03    1.01, 1.04    0.002^\#\#^
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Prostate primary tumors: patient n = 261 for all models except multivariable model with mutation burden, where n = 227; event n = 33; median follow-up time for survivors 40 (IQR 25,81) months.

†Prostate metastatic tumors: patient n = 216 for all models except multivariable model with mutation burden, where n = 205; event n = 80; median follow-up time for survivors 59.5 (IQR 32, 129) months.

‡Pan-cancer primary tumors, univariate models: patient n = 6610, event n = 1535, median follow-up time for survivors 24 (IQR 11, 61) months.

§Pan-cancer metastatic tumors, univariate models: patient n = 4864, event n = 1467, median follow-up time for survivors 51 (IQR 23, 109) months.

\#Pan-cancer meta-analysis, among ten most prevalent cancer types: primary tumor patient n = 4863, metastatic tumor patient n = 3676. Estimates are based on overall fixed effects.

\*\*p-value corresponds with test of effects size. Chi-square test for heterogeneity p-value=0.003.

††p-value corresponds with test of effects size. Chi-square test for heterogeneity p-value=0.024.

‡‡Exclusion of cancer types to reduce heterogeneity: primary tumor patient n = 3887, metastatic tumor patient n = 3098. Estimates are based on overall fixed effects.

§§Excluding pancreatic and colorectal cancer, test of effects size p-value. Chi-square test for heterogeneity p-value=0.3.

\#\#Excluding pancreatic and prostate cancer, test of effects size p-value. Chi-square test for heterogeneity p-value=0.8.

Since clinical sequencing assays also provide point mutation information for several hundred cancer genes, we asked if tumor CNA burden is prognostic after adjusting for known prostate cancer driver alterations. In separate multivariable regression models adjusting for *TP53*, *RB1*, or *PTEN* loss and/or mutation, tumor CNA burden is still associated with overall survival independent of these alterations in primary prostate tumors ([Table 3](#table3){ref-type="table"}). In metastatic tumors, these specific gene mutations do not reach prognostic significance when combined with tumor CNA burden ([Table 3](#table3){ref-type="table"}). Notably, tumor CNA burden remains significant in metastatic tumors after adjusting for overall tumor mutation burden (per 5% tumor CNA burden, HR = 1.08; 95% CI = 1.02, 1.15; p=0.011; [Table 3](#table3){ref-type="table"}).

As targeted clinical sequencing is applied to a wide range of cancer types, we expanded our survival analysis to a pan-cancer cohort, consisting of 6610 primary tumors and 4864 metastatic tumors across 53 cancer types assayed by MSK-IMPACT sequencing panel (Materials and methods and [Supplementary file 2](#supp2){ref-type="supplementary-material"}). We find that tumor CNA burden is prognostic for overall survival pan-cancer in primary tumors (p\<0.0001; per 5% tumor CNA burden, HR = 1.04; 95% CI, 1.02, 1.05) and in metastatic tumors (p=0.005; per 5% tumor CNA burden, HR = 1.02; 95% CI, 1.01, 1.03) in a univariate analysis of these pan-cancer cohorts ([Table 3](#table3){ref-type="table"}, [Figure 2c](#fig2){ref-type="fig"}). Tumor CNA burden is also prognostic for cancer-specific death in the metastatic tumor cohort (p=0.026; per 5% tumor CNA burden, HR = 1.05; 95% CI, 1.01, 1.10). Adjustment for sample tumor purity determined by FACETS ([@bib31]) found that CNA burden was still significantly associated with overall survival in primary tumors in the pan-cancer analysis and approached significance for metastatic tumors (p=0.06; [Supplementary file 3](#supp3){ref-type="supplementary-material"}), though purity-adjusted CNA burden was no longer significantly associated with overall survival in the prostate tumor subsets ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). Adjustment for sample tumor purity determined by FACETS ([@bib31]) found that CNA burden was still significantly associated with overall survival in primary tumors in the pan-cancer analysis approached significance for metastatic tumors (p=0.06; [Supplementary file 3](#supp3){ref-type="supplementary-material"}), though purity-adjusted CNA burden was no longer significantly associated with overall survival in the prostate tumor subsets ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). Tumor mutation burden (TMB), in contrast to tumor CNA burden, was not associated with overall survival or cancer-specific survival (p=0.4 and p\>0.9, respectively; [Table 3](#table3){ref-type="table"}).

Since the pan-cancer prognostic significance of tumor CNA burden is likely to be influenced by the distribution of cancer types within the IMPACT cohorts, we stratified the primary and metastatic pan-cancer IMPACT cohorts by their ten most prevalent cancer types, which make up nearly three-quarters of the cohort ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). A multivariable Cox model was used for each cancer type to adjust for mutation burden and extract the effect size, which was then entered into a meta-analysis. After stratifying by cancer type, the CNA burden of primary tumors measured by the MSK-IMPACT assay is still significantly associated with death (overall fixed effects HR = 1.04; 95% CI 1.02, 1.05; test of effects size p\<0.0001; [Table 3](#table3){ref-type="table"}; [Figure 2c](#fig2){ref-type="fig"}). Similarly, metastatic tumor CNA burden was associated with death (overall fixed effects HR = 1.02; 95% CI 1.01, 1.04; test of effects size p=0.005; [Table 3](#table3){ref-type="table"}; [Figure 2c](#fig2){ref-type="fig"}).

A closer look at the pan-cancer analysis reveals statistically significant heterogeneity in the relationship between tumor CNA burden and survival across tumor types (p=0.003 and p=0.024 in primary and metastatic tumor cohorts respectively, [Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). In primary tumors, heterogeneity appears to be driven by colorectal and pancreatic cancers, where an inverse association between tumor CNA burden and death is seen ([Figure 2---figure supplement 5a](#fig2s5){ref-type="fig"}). After excluding colorectal and pancreatic cancers, heterogeneity is no longer statistically significant (overall fixed effects HR = 1.05; 95% CI 1.03, 1.07; test of effects size p\<0.0001; test for heterogeneity p=0.3; [Figure 2---figure supplement 5a](#fig2s5){ref-type="fig"}). In metastatic tumors, two outlying cancer types drive this heterogeneity: pancreatic cancer, which shows the same inverse association of tumor CNA burden with death as in primary pancreatic tumors, and prostate, which shows the opposite effect ([Figure 2---figure supplement 5b](#fig2s5){ref-type="fig"}). Exclusion of either cancer type eliminates the significant heterogeneity in effects size, such that higher tumor CNA burden is associated with increased death in the remaining homogenous set of cancer types (overall fixed effects HR = 1.03; 95% CI 1.01, 1.04; test of effects size p=0.002; test for heterogeneity p=0.8, [Figure 2---figure supplement 5b](#fig2s5){ref-type="fig"}). These results indicate that tumor CNA burden can have differing levels of prognostic effect depending on the cancer type, while a core set of cancer types show a statistically similar association between overall survival and tumor CNA burden assayed by targeted sequencing. More generally, we find that tumor CNA burden determined by a clinically-certified sequencing panel is associated with overall and disease-specific mortality in a large multi-cancer population, including in patients with metastatic cancer where clinical sequencing is increasingly applied.

Discussion {#s3}
==========

Many specific genes altered by CNA have been associated with cancer outcomes ([@bib25]; [@bib40]; [@bib28]), however the relationship between outcome and the overall level of CNA harbored by a tumor is less well studied. Here we expanded on our previous work showing that tumor CNA burden is associated with recurrence in surgically treated primary prostate cancer ([@bib32]; [@bib22]) by showing a significant association with death from prostate cancer, including in conservatively treated patients where the tumor CNA burden measurement was made from biopsies. Importantly, this association remains significant even after adjusting for Gleason score or for CAPRA score, demonstrating that CNA burden is independent of previously identified associations with these measures of cancer pathology or disease state. Thus, tumor CNA burden assessment from prostate biopsies could have a role in deciding between surgery and surveillance for men at the low end of intermediate risk. Conversely, it may also have role in men at high risk where multimodal treatment may be needed.

An unanticipated outcome of our analysis beyond prostate cancer is the prognostic role of tumor CNA burden across a range of tumor types. The pan-cancer tumor CNA burden association is significant but also heterogeneous depending on cancer type. Recent work has similarly found that the presence of any CNA, regardless of gene identity, is associated with overall and event-free survival in pediatric AML ([@bib37]) and that the percentage of subclonal CNAs but not subclonal somatic point mutations is associated with overall survival in non-small cell lung cancer ([@bib24]). Moreover, survival time was associated with a CNA signature derived from supervised analyses in prostate cancer and extended to breast and lung cancer ([@bib29]). Prognostic individual CNAs or sets of CNAs, as opposed to the broader measure of genome-wide CNA level examined here may be specific to individual cancer types, whereas we have demonstrated the prognostic potential of a generalized measure of overall copy number dysregulation. Further work will be needed to address the trade-offs between generalizability of CNA burden and discriminatory power. In addition, it will be important to investigate whether the prognostic associations of CNA burden from the pan-cancer analysis are independent of known cancer- or subtype-specific prognostic factors, such as ER receptor status in breast cancer, ultra- and hypermutated (POLE and MSI+) status in endometrial cancer and MSI-positive/CIN-negative status in colorectal cancer ([@bib39]).

We find it notable that tumor CNA burden assessment using a targeted sequencing can serve as a surrogate for tumor CNA burden calculated using more comprehensive genomic assays such as array CGH. With the proliferation of different clinical sequencing panels for mutation detection, it will be of interest to see how much resolution, depth, and coverage can be reduced and still retain the prognostic association of CNA burden; future work in this area will also need to incorporate the predictive clinical utility of the point mutation data to address the multimodal uses of clinical sequencing assays. Another important variable is tumor purity. The prognostic significance of CNA burden can be affected by sample tumor purity, with purity being independently associated with outcome. The effect of purity on the association between CNA burden and outcome appears complex and may be influenced by the analysis platform, cancer type, and outcome type. For example, pan-cancer CNA burden from clinical sequencing panel remained prognostic for survival after purity adjustment in primary tumors and was just below significance for metastatic tumors, though the CNA burden of the prostate tumor subset assayed by IMPACT sequencing panel did not. However, the CNA burden of prostate tumors assayed by SNP array showed continued association with recurrence after adjustment for purity. Tumor purity alone was also independently associated with survival, revealing a complex interaction between these tumor features that will need further exploration. As targeted sequencing moves from tumor samples to liquid biopsy in the form of cell-free DNA (cfDNA) ([@bib21]; [@bib42]; [@bib23]), it will be important to determine whether tumor CNA burden determined by analysis of cfDNA has similar prognostic utility as that determined by direct analysis of tumor DNA. There is already some evidence this may be possible, as the summed CNA level of the most highly copy number altered genes assayed from whole genome sequencing of cfDNA in twenty metastatic prostate cancer patients correlated with overall survival ([@bib42]). As sequencing costs continue to drop and computational power improves, it would be interesting to investigate low pass whole genome sequencing as an alternative approach for determining tumor CNA burden that provides complete genome coverage.

Another interesting feature of the association of tumor CNA burden with outcome demonstrated here is that it has prognostic significance independent of tumor mutation burden (TMB). This is consistent with recent work in glioblastoma, breast, lung, and ovarian cancer showing that CNA-derived signatures have more prognostic power than somatic point mutation-based signatures, as measured by concordance index ([@bib19]). Thus, tumor CNA burden could complement clinical analyses of actionable driver mutations using a single panel-based sequencing assay.

The prognostic significance of tumor CNA burden raises intriguing questions regarding the underlying biology. Tumor CNA burden may be a simple measure that correlates with the extent of oncogenic driver alterations. Yet, we show that tumor CNA burden retains its prognostic significance after adjustment for a number of known oncogenic alterations in primary prostate cancer, including PTEN loss associated with increased tumor CNA burden ([@bib12]; [@bib41]). In metastatic tumors, combining tumor CNA burden with TP53 or RB1 loss in multivariable analyses renders both slightly below conventional significance thresholds, raising the possibility of biological interplay between these genes (particularly TP53) and subsequent copy number alteration that develops during tumor evolution. Further, the prognostic associations of tumor CNA burden are independent of tumor ploidy, which suggests that tumor CNA burden may not simply reflect aneuploidy, defined as abnormal DNA content ([@bib18]). It is also possible that tumor CNA burden captures prognostic information about currently unidentified driver alterations and/or the rate of ongoing CNA within a tumor that may generate additional driver alterations, including those reflecting intratumoral heterogeneity, thereby affecting outcome. Ongoing work by others has begun to develop genomic methods for identifying mechanisms of somatic CNA ([@bib38]); and identify prognostic CNA signatures and the mechanisms underlying the component CNA ([@bib27]). Ultimately, the biology underlying the significant association of tumor CNA burden with multiple cancer outcomes will be a fruitful area for future investigation.

Materials and methods {#s4}
=====================

aCGH copy number analysis of conservative-treatment TAPG cohort. {#s4-1}
----------------------------------------------------------------

Of the TAPG1 cohort ([@bib17]), FFPE prostate tumor tissue from 180 patients was macrodissected from slides. DNA was isolated (Agilent FFPE DNA isolation for aCGH protocol) and quantified by picogreen-based quantification. 107 cases yielded greater than 500 ug DNA and were analyzed by Agilent 180K human CGH arrays (Agilent, 4 × 180K G4449A arrays, per manufacturer\'s instructions). Copy number data from patients in the TAPG copy number cohort were quantified, normalized, segmented, and analyzed with RAE, as previously described ([@bib32]; [@bib22]). The conservative treatment TAPG copy number cohort array data was deposited in NCBI GEO under accession number GSE103665 (Gene Expression Omnibus, RRID:[SCR_007303](https://scicrunch.org/resolver/SCR_007303)).

Tumor CNA burden (tumor CNA burden) was analyzed as percent CNA burden, defined as the length of the genome altered by copy number alteration multiplied by 100. For regression analyses, tumor CNA burden was scaled as per five percent so that the estimates of our hazard ratios were more interpretable. All statistical analyses were performed using Stata 13 (RRID:[SCR_012763](https://scicrunch.org/resolver/SCR_012763), StataCorp, College Station, TX).

TAPG copy number cohort statistical analyses {#s4-2}
--------------------------------------------

For Cox regression analyses, the primary aim was to determine whether tumor CNA burden is associated with cancer specific survival (CSS). First, we assessed whether there was an association between tumor CNA burden and CSS by utilizing a univariate Cox model, censoring patients who did not die at the date of their last follow-up and patients who died of other causes at their death date. Secondly, in order to assess whether there is information from tumor CNA burden over and above biopsy Gleason score, we utilized a multivariable Cox model, adjusting for biopsy Gleason sum categorized as ≤6, 7, and ≥8. Finally, to assess whether there is an association between tumor CNA burden and CSS after accounting for the preoperative predictors of CSS, we utilized a multivariable Cox model, adjusting for the UCSF-CAPRA score, a preoperative risk score calculated by incorporating the patient's age at diagnosis, PSA at diagnosis, primary and secondary Gleason score at biopsy and clinical tumor stage. As percent of positive biopsy cores was not available for the cohort, a modified CAPRA score was utilized not incorporating this information. Among our cohort of 107 patients, 47 patients were missing clinical tumor stage; multiple imputation was used to impute the missing values. Statistical analyses were performed utilizing the measured and imputed values combined across 10 imputations using Rubin's method. Furthermore, to evaluate the discriminative accuracy of the model including tumor CNA burden, we calculated bootstrap optimism-corrected Harrell's C-index. It should be noted that the discrimination of the CAPRA score is lower in the TAPG1 conservative treatment CNA cohort than seen in some other prostate cancer cohorts, and this may impact the degree to which tumor CNA burden increases the concordance index. All data used for these analyses are available in [Supplementary file 4](#supp4){ref-type="supplementary-material"}.

For illustrative purposes, we utilized competing risk methods to estimate the probability of death from prostate cancer in the setting of death from other causes. Cumulative incidence was shown for patients who died from prostate cancer, or died from other causes, stratified on tumor CNA burden in relation to the median tumor CNA burden among the cohort, using the *stcompet* command in Stata.

Statistical analyses of IMPACT cohorts {#s4-3}
--------------------------------------

For analysis of the prostate cancer MSK-IMPACT cohort ([@bib1]), the published cases were analyzed by Cox regression for association between overall survival and tumor CNA burden ([Supplementary file 5](#supp5){ref-type="supplementary-material"} and [6](#supp6){ref-type="supplementary-material"}). The IMPACT cases were separated into groups consisting of primary tumors or metastatic tumors, including loco-regional, non-resistant to treatment, and treatment resistant, though primary tumor samples include cases sampled after metastatic spread. Among our primary and metastatic IMPACT prostate cancer cohorts, we excluded men with unknown overall survival status and unknown time until overall survival status, leaving us with a final cohort of 261 and 216 men, respectively. Among these two groups of patients, we assessed the association between tumor CNA burden and overall survival using a univariate Cox model. Multivariable Cox models were then used to determine whether the association between tumor CNA burden and overall survival remained after accounting for purity determined by FACETS ([@bib31]), the overall point mutation burden, or specific somatic gene alterations (shallow or deep copy number loss or mutation) occurring in prostate cancer (*BRCA1, BRCA2, ATM, TP53, RB1*, and *PTEN*), using separate models for each alteration. As the overall point mutation burden was not available for all patients, 34 patients with primary prostate cancer and 11 patients with metastatic prostate cancer were excluded from this portion of the analysis in their respective cohorts.

For analysis of our pan-cancer IMPACT cohort (MSK-IMPACT cohort ([@bib44]) and additionally accrued IMPACT samples), outcome data at time of analysis, mutation burden, and fraction genome altered data used were derived and available in updated form the cBio Portal (RRID:[SCR_002877](https://scicrunch.org/resolver/SCR_002877), <http://www.cbioportal.org/study?id=msk_impact_2017>, samples and annotation used at time of analysis available as [Supplementary file 7](#supp7){ref-type="supplementary-material"} and [8](#supp8){ref-type="supplementary-material"}). A cohort of 7305 primary tumor cases across 53 different cancer types and a cohort 5907 metastatic tumor cases, across 47 different cancer types, were identified. Within the primary and metastatic disease cohorts, we excluded patients with unknown tumor CNA burden, overall survival status, unreported follow-up time, death or censoring immediately after treatment, unknown cancer type, and unknown mutation burden. The final cohort used here therefore included 6610 and 4864 patients, respectively. Within both of these cohorts, univariate Cox models were used to determine whether CNA or mutation burden is associated with overall survival. Reported follow-up time was used. As it is probable that the association between tumor CNA burden and survival likely varies based on the particular cancer type, we focused on patients with the ten most prevalent cancer types in both of the respective cohorts ([Supplementary file 2](#supp2){ref-type="supplementary-material"}, 5198 and 3886 patients with primary and metastatic disease respectively) and proceeded with a meta-analysis in order to stratify by cancer type. In particular, we utilized a multivariable Cox model, adjusting for mutation burden for each cancer type and extracted the effect size. The effect size for each cancer type was then entered into a meta-analysis using the *metan* command in Stata. Both fixed effects and random effects estimates were calculated. Fixed effects weights were calculated using inverse-variance weighting, *metan* weights were calculated using the DerSimonian and Laird method.

Statistical analyses of TCGA cohorts {#s4-4}
------------------------------------

For analyses of TCGA cohorts, the following published cohorts were filtered for only primary, non-neoadjuvantly treated cases and analyzed: TCGA prostate adenocarcinoma (2015) ([@bib10]), breast carcinoma ([@bib15]), uterine endometriod cancer ([@bib8]), renal clear cell carcinoma ([@bib7]), papillary thyroid carcinoma ([@bib9]), and colorectal adenocarcinoma ([@bib6]). The number of cases and exclusions based on unavailable data are detailed in [Supplementary file 9](#supp9){ref-type="supplementary-material"}. Cox regression was used to test the association of tumor CNA burden as a continuous variable with (i) cancer free status and (ii) overall survival in univariate models and in multivariable models with disease stage. For the TCGA colorectal cancer cohort, tumor stage was also used. For the TCGA prostate adenocarcinoma cohort, multivariable Cox regression models that included Gleason score, mutation count, ploidy, and/or ABSOLUTE purity ([@bib11]) originally reported with this cohort were also used. Analyses including purity exclude 37 patients without absolute tumor purity measured, resulting in analysis with 243 men, 29 of whom had BCR, and a median followup time for survivors of 20.1 (7.0, 37.9) months.

Data access. The conservative treatment TAPG copy number cohort array data was deposited in NCBI GEO (Gene Expression Omnibus, under accession number GSE103665 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103665>).
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All data generated or analysed during this study are included in the manuscript and supporting files and reference materials. The conservative treatment TAPG copy number cohort array data was deposited in NCBI GEO under accession number GSE103665 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103665>).

The following dataset was generated:

Hieronymus HTaylor BSSawyers CL2018Copy number alteration burden is a pan-cancer prognostic factor associated with metastasis and death in conservatively treated prostate cancer: TAPG1 CNA cohort aCGH data<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE103665>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE103665).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death\" for consideration by *eLife*. Your article has been reviewed by Jeffrey Settleman as the Senior Editor, Michael Green as the Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Cory Abate-Shen (Reviewer \#1); Mark A Rubin (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript analyzed the CNA landscape of conservatively treated prostate cancer in a historic biopsy and transurethral resection cohort and found that increased abundance of CNA in tumors is correlated with recurrence and mortality. This finding was further extended across multiple cancer types by analyzing data from TCGA and other cohorts. Given the prevalence of CNA throughout cancer genomes, this study highlights the potential for incorporating overall CNA burden assessment as a molecular prognostic factor in treatment decision making.

The reviewers agreed that the approach is rigorous and addresses important aspects of biomarker evaluation including taking into account clinical and pathology parameters. The reviewers also felt that the manuscript is clear and well-written. However, the reviewers also expressed a concern about the novelty of the results in the light of previously published work, as elaborated below. The reviewers would like to see your response to these concerns in a point-by-point response letter and in a revised manuscript before committing to a decision regarding appropriateness for publication in *eLife*.

Essential revisions:

1\) The authors state that they are surprised by the findings that CNVs have such a strong association with clinical progression for prostate and other cancers. Yet, this is known in the prostate cancer research community and has been previously reported on in different eras based on available technology. Therefore, it would be reasonable for the authors to consider their finding in the context of the prior knowledge. For example, comparative genomic hybridization (CGH) technology led to some of the first genome-wide observations regarding copy number alterations and disease state (Cher et al., 1994; Visakorpi et al., 1995). CGH identified somatic copy number alterations in a high percentage (\~75%) of localized PCA. Losses were found to be 5 times more common than gains and most often involved 8p (32%), 13q (32%), 6q (22%), 16q (19%), 18q (19%), and 9p (16%). These early genome-wide studies also suggested that the pattern of copy number alterations changes with disease progression. For example, gains of 7, 8q, and X were more often observed in the CRPC state (Visakorpi et al., 1995). SNP arrays also very nicely accessed CNV (Dumur et al., 2003; Lin et al., 2004). These platforms were used by the TCGA studies to perform a comprehensive copy number analysis for localized PCA (Cancer Genome Atlas Research Network. Electronic address and Cancer Genome Atlas Research, 2015). As well as a prior meta-analysis that showed recurrent CNVs were associated with disease progression (Williams et al., 2014). (Note: This paper is referenced in the text but for a more focused point). These are just a selection. There are others.

2\) Related to the above comment, if the major point is that these new datasets add substantially more information, it would be nice to show a down-sizing experiment in silico wherein decreasing the coverage means the signal that supports these associations is lost. What is the minimal coverage needed to make these associations? This is important due to prior work that used older technologies to make similar claims.

3\) There is recent published work that appears to be very similar. Pearlman et al., (2018) report, \"pan-cancer metastasis potential score (panMPS) based on observed CNAs\". panMPS predicts metastasis and metastasis-free survival in cohorts of patients with prostate cancer, triple negative breast cancer and lung adenocarcinoma, and overall survival in the Metabric breast cancer cohort and three cohorts from The Cancer Genome Atlas (TCGA), including prostate, breast and lung adenocarcinoma. And Ross-Adams et al., (2015) explored risk in association with CNV and integrating transcriptomic data, albeit on smaller prostate cancer data sets. These studies and work reported in bioRχiv from the ICGC groups on structural variation might also be valuable to include in a discussion of recent relevant prior work in this field.

4\) Is the association between CNA burden and survival in prostate cancer explainable by differences in purity? Impure samples will have low apparent CNA burden.

5\) The manuscript points out that \"aneuploidy\" but not \"CNA burden\" has previously been associated with outcome. In many cases, \"aneuploidy\" referred not to overall changes in tumor ploidy, e.g. due to genome doubling, but indeed to something similar to CNA burden. \"Chromosomal instability\" has also been used to describe the same phenomenon and has been associated with prognosis in multiple cancers. For example: Murayama-Hosokawa et al., 2010 (endometrial cancer); Walther et al., 2008; Mouradov et al., 2013; and Berg et al., 2015 (colorectal cancer, and making the important point that the relationship with CIN or CNA burden may reflect absence of MSI); Karlsson et al., 2007 (breast cancer); and Carter et al., 2006 (multiple cancer types).

6\) The overall association between CNA burden and survival may be obscuring negative associations between specific CNAs and survival. Have the authors evaluated the association between specific CNAs and survival, after controlling for overall CNA burden?

10.7554/eLife.37294.027

Author response

> Essential revisions:
>
> 1\) The authors state that they are surprised by the findings that CNVs have such a strong association with clinical progression for prostate and other cancers. Yet, this is known in the prostate cancer research community and has been previously reported on in different eras based on available technology. Therefore, it would be reasonable for the authors to consider their finding in the context of the prior knowledge. For example, comparative genomic hybridization (CGH) technology led to some of the first genome-wide observations regarding copy number alterations and disease state (Cher et al., 1994; Visakorpi et al., 1995). CGH identified somatic copy number alterations in a high percentage (\~75%) of localized PCA. Losses were found to be 5 times more common than gains and most often involved 8p (32%), 13q (32%), 6q (22%), 16q (19%), 18q (19%), and 9p (16%). These early genome-wide studies also suggested that the pattern of copy number alterations changes with disease progression. For example, gains of 7, 8q, and X were more often observed in the CRPC state (Visakorpi et al., 1995). SNP arrays also very nicely accessed CNV (Dumur et al., 2003; Lin et al., 2004). These platforms were used by the TCGA studies to perform a comprehensive copy number analysis for localized PCA (Cancer Genome Atlas Research Network. Electronic address and Cancer Genome Atlas Research, 2015). As well as a prior meta-analysis that showed recurrent CNVs were associated with disease progression (Williams et al., 2014). (Note: This paper is referenced in the text but for a more focused point). These are just a selection. There are others.

We thank the reviewers for highlighting this and appreciate the well demonstrated connection of specific CNVs and CNV signatures (derived from supervised analyses) to disease state in prostate cancer. We have expanded our consideration of this in the Introduction and Discussion section. As the reviewers note, CNV patterns or clusters have been associated with Gleason 8+ disease (compared to Gleason 6-7, Williams et al., 2014) and recurrent disease (compared to primary, Visakorpi et al., 1995, 2015). Indeed, our group initially found CNA patterns associated with shorter time to biochemical recurrence in prostate cancer (Taylor et al., 2010). Nonetheless, previous studies have primarily looked at the association of individual or sets of CNVs with pathology and disease state, rather than outcomes themselves and time to outcome.

The novelty of the work presented in our study lies in the association of (1) high quality clinical endpoints across cancer types and in a pan-cancer cohort with (2) the overall level or burden of genomic CNA of a tumor, agnostic to the identity of the component CNAs. Moreover, we adjust for prognostic pathological features which have previously been linked to CNVs, showing that association of CNA burden with outcome is independentof the previously published association with pathology features or disease state. We have expanded on this in the discussion to address the reviewers' comments.

The key novel insight is the following: specific prognostic CNVs are likely to be cancer specific, whereas here we show the prognostic potential of a generalized measure of overall copy number dysregulation, as well as the feasibility of measuring this dysregulation using a current clinical NGS test. We acknowledge that the concept of CNA burden as a prognostic factor could seem rather obvious, at first glance, if viewed as a summation that includes all specific prognostic CNVs. But CNA burden could include both positive and negative prognostic CNVs that counterbalance this. Our work demonstrates that the prognostic utility of overall CNA burden is not lost in the noise of CNAs that are unassociated or negatively associated with poor outcome.

> 2\) Related to the above comment, if the major point is that these new datasets add substantially more information, it would be nice to show a down-sizing experiment in silico wherein decreasing the coverage means the signal that supports these associations is lost. What is the minimal coverage needed to make these associations? This is important due to prior work that used older technologies to make similar claims.

This is an interesting question that raises a number of issues about coverage, resolution, and depth of genome sampling in assaying tumor copy number, both in newer sequencing approaches and older approaches such as array-based methods. The effective coverage of the genome is similar between targeted sequencing by IMPACT (due to the inclusion of SNP probes to specifically address the coverage question) versus older aCGH approaches (used for our conservative treatment cohort) as well as whole exome sequencing. Specifically, the method of calculating burden from the IMPACT targeted sequencing data incorporates SNP probes throughout the genome. We have updated the description of how CNA burden is calculated from IMPACT to clarify this. To illustrate the similarity in breadth of coverage between these technologies, we have added the prostate cohort analyzed by targeted IMPACT assay to Figure 1A. As shown with this addition, the coverage is similar with the newer clinically approved technology.

Rather than running a downsizing experiment, we took advantage of a pan-cancer IMPACT cohort for which whole exome sequencing was also performed (n=1005) and ran an upsizing experiment. The CNA burden determined by targeted IMPACT assay and by whole exome sequencing is highly correlated (rho=0.88, p-value\<0.0001, Figure 2---figure supplement 3). We have added this analysis to the Results section and Discussion section. While the suggestion for a further downsizing experiment is interesting, we feel the IMPACT versus WES comparison addresses the main point raised by the referee. Efforts to further downsize from IMPACT to determine the minimal coverage required for prognosis determination is beyond the scope of this initial report and would best benefit from incorporation of other prognostic clinical markers.

> 3\) There is recent published work that appears to be very similar. Pearlman et al., (2018) report, \"pan-cancer metastasis potential score (panMPS) based on observed CNAs\". panMPS predicts metastasis and metastasis-free survival in cohorts of patients with prostate cancer, triple negative breast cancer and lung adenocarcinoma, and overall survival in the Metabric breast cancer cohort and three cohorts from The Cancer Genome Atlas (TCGA), including prostate, breast and lung adenocarcinoma. And Ross-Adams et al., (2015) explored risk in association with CNV and integrating transcriptomic data, albeit on smaller prostate cancer data sets. These studies and work reported in bioRχiv from the ICGC groups on structural variation might also be valuable to include in a discussion of recent relevant prior work in this field.

We thank the reviewers for bringing our attention to the recent work by Pearlman et al., (2018). We have added a discussion of this study and how it derives a 295-gene frequency-weighted CNA signature derived by supervised analysis of prostate metastases that is prognostic for metastasis and overall survival in prostate and breast cancer. It is interesting to note that CNA burden outperforms their signature in one prostate cohort, while their signature outperforms CNA burden in the other prostate cohort they analyze (one in which PSA and stage are not prognostic). As a set of CNAs selected from prostate cancer, it may have less generalizable prognostic significance beyond the two cancers examined. We expand on this with some of the recent studies showing that CNA frequency, independent of identity, is associated with survival in pediatric AML (Vujkovic et al., 2017) and NSC lung cancer (Jamal-Hanjani et al., 2017). We have also added some discussion of prepublication results from ICGC and others (available on BioRχiv) on somatic CNA in cancer with regards to CNA, prognosis, and mechanism.

> 4\) Is the association between CNA burden and survival in prostate cancer explainable by differences in purity? Impure samples will have low apparent CNA burden.

This is an important question which we have addressed with several additional analyses. First, we looked at the association between CNA burden and outcome in the TCGA prostate cohort after adjusting for purity using the ABSOLUTE purity metric, which was reported with the first publication of this cohort and represents a standard computationally-determined measure of purity. We find that CNA burden is still prognostic for recurrence after adjusting for sample tumor purity in the TCGA cohort (Table 2 and Results section). It is also still prognostic after adjusting for tumor purity along with Gleason and/or mutation burden, but these additional multivariate models are overfitted and we therefore elected not to include them in the revised manuscript. Next, we analyzed the IMPACT cohorts after adjusting for purity. Importantly, purity in these cohorts is more variable since these samples are not subject to the quality control requirements mandated by TCGA (typically \>70% tumor content). We found that CNA burden in prostate tumors falls below the significance of association with overall survival when adjusting for purity determined by FACETS. However, purity-adjusted CNA burden is still significant in the pan-cancer primary tumor cohort and approaches significance in the metastatic tumor cohort (Supplementary file 3 and Results section).

This variability may in part be influenced by the smaller hazard ratio of CNA burden determined by IMPACT (sequencing panel) assay versus arrays (TCGA and TAPG/conservative treatment cohort) in these respective cohorts. It is also worth noting that a subset of samples in the IMPACT prostate cohort could not be included in the purity-adjusted analysis due to computational limitations in the purity calculation. Due to this limitation, we saw a decrease in the significance of association between mortality and CNA burden even before adjusting for purity, given with this smaller number of cases (P = 0.007 in the full cohort versus P = 0.02 in the subset for which a purity calculation was available).

In summary, tumor purity is a potentially significant variable that modulates CNA prognostic significance, and it will be important to continue to explore its effect especially in the context of additional molecular prognostic factors. It is interesting that within the IMPACT cohort, purity itself is associated with outcome and may warrant further investigation in such work. We have added a discussion of these considerations to the Discussion section.

> 5\) The manuscript points out that \"aneuploidy\" but not \"CNA burden\" has previously been associated with outcome. In many cases, \"aneuploidy\" referred not to overall changes in tumor ploidy, e.g. due to genome doubling, but indeed to something similar to CNA burden. \"Chromosomal instability\" has also been used to describe the same phenomenon and has been associated with prognosis in multiple cancers. For example: Murayama-Hosokawa et al., 2010 (endometrial cancer); Walther et al., 2008; Mouradov et al., 2013; and Berg et al., 2015 (colorectal cancer, and making the important point that the relationship with CIN or CNA burden may reflect absence of MSI); Karlsson et al., 2007 (breast cancer); and Carter et al., 2006 (multiple cancer types).

We thank the referees for calling attention to thee related concepts of CNA burden, aneuploidy, and chromosomal instability. Aneuploidy has predominantly been defined as having a non-diploid DNA index, generally assayed by cytometry (e.g. Walther et al., 2008, which we thank the reviewers for directing our attention to, provides a metastudy which uses this metric for aneuploidy; Danielsen et al., 2016). The ploidy metric (determined by CLONET) used in our manuscript to adjust for aneuploidy in our multivariable regression model reflects the same information as DNA index conventionally used to measure aneuploidy. Indeed, ploidy estimates from SNP and sequencing data, such as the one we use, have been successfully benchmarked against FACS and SKY-determined DNA index in human tumors and cell lines (Carter et al., 2012; Prandi et al., 2014). Therefore, we believe our conclusion that the prognostic significance of CNA burden is independent of aneuploidy reflects the traditional measure of aneuploidy in prognostic significance.

However, we understand that aneuploidy has various, often more mechanistic, definitions (e.g., numerical aneuploidy/CIN and structural aneuploidy/GIN), some of which are not captured by ploidy as numerical DNA index. To address the reviewers' points, we have clarified how the ploidy used in our analysis was determined and its relationship to ploidy and DNA index used in prognostic studies of aneuploidy or chromosomal instability (Results). We have also qualified our conclusion from this finding in the discussion to take into consideration the way aneuploidy was measured. We have also expanded the discussion of how future work will be needed to determine if CNA burden is prognostic independent of cancer type-specific prognostic classifications, including MSI-positive status in colorectal cancer which, as the reviewers note, is largely exclusive with CIN-positive status and may be involved in the prognostic interplay between CNA burden and CIN status (including Berg et al., 2015).

> 6\) The overall association between CNA burden and survival may be obscuring negative associations between specific CNAs and survival. Have the authors evaluated the association between specific CNAs and survival, after controlling for overall CNA burden?

We looked for the association between survival and selected specific CNAs in multivariable regression models with CNA burden in prostate cancer (Table 3 and Materials and methods section). This analysis was focused on the question of whether the specific CNAs we examined accounted for the prognostic significance of CNA burden, and we found that they did not. These specific CNAs did have negative associations with survival (positive association with mortality) for the most part (or no significant association) and their negative associations with survival were not strengthened by the adjustment for CNA burden through its inclusion in the model.

The question about whether there are specific CNAs that have a positive association with survival that might be obscured by CNA burden is interesting and worthy of future exploration. We believe that many individual prognostic CNAs are likely to be cancer type-specific, and current cohorts unfortunately do not have sufficient size to run individual regressions for all CNAs to uncover these in a rigorous fashion.
